Transdermal Scopolamine Patch with Odansetron for the Control of Nausea after Uterine Artery Embolization Compared with Odansetron Alone: Results of a Randomized Placebo–Controlled Trial

Lee, Justin S.; Costantino, Mary; McCullough, Michael F.; Lee, Jaime B.; Jones, Michelle M.; Carter, Elizabeth A.; Spies, James B.

doi:10.1016/j.jvir.2010.02.035

Cited by 6 publications

(11 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nausea levels overall were low, with mean scores for all patients of 2.63 on Day 1 and 1.35 on Day 2. Transdermal scopolamine patients scored 1.8 ± 2.6 for nausea on Day 1 compared with 3.4 ± 3.5 for placebo patients (P = 0.03), but the difference was not significant on Day 2 [53].…”

Section: Transdermal Scopolamine Combined With Other Agents And/or Comentioning

confidence: 84%

“…Furthermore, the multiple (and possibly interactive) targets of scopolamine actions (both peripheral and central) complicate the direct relationship between effect and blood concentration. Supporting this view: first, the pharmacokinetics of transdermal scopolamine are best modeled by a multi-compartment model rather than a Table 2 Overview of several studies evaluating the efficacy of transdermal scopolamine for postoperative nausea and vomiting or postdischarge nausea and vomiting (PONV/PDNV) prophylaxis [28][29][30]43,[45][46][47][48][49][50][51][52][53][54][55][56] single-compartment model [41] and, second, there is considerable variability in plasma concentration among individuals who respond to the drug. For instance, in one typical study, the mean plasma concentration of scopolamine in those experiencing an antiemetic effect had a standard error that was nearly half as large as the mean itself (157 ± 77 pg/ mL) [42].…”

Section: Pharmacokineticsmentioning

confidence: 99%

“…Further, ondansetron was available in 4-mg doses every 6 hours as needed [53]. Patients were randomized to receive a transdermal scopolamine or sham patch, applied while the patient was in the holding area.…”

Section: Transdermal Scopolamine Combined With Other Agents And/or Comentioning

confidence: 99%

“…Further study of longer-term antiemetic effects of transdermal scopolamine (24 to 72 hrs) is warranted. Table 3 Overview of adverse events reported in clinical trials of transdermal scopolamine [28][29][30]43,[45][46][47][48][49][50][51][52][53][54][55][56] Study Surgery N Design Adverse events Bailey et al [45] Outpatient laparoscopy 138 TDS vs placebo AEs mild but more frequent in TDS than placebo pts (91% vs 45%, P b 0.05). Einarsson et al [46] GYN laparoscopy 48 TDS vs placebo AEs mild.…”

Section: Timing Of Patch Applicationmentioning

confidence: 99%

See 3 more Smart Citations

Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting

Pergolizzi¹,

Philip²,

Leslie³

et al. 2012

Journal of Clinical Anesthesia

View full text Add to dashboard Cite

Section: Transdermal Scopolamine Combined With Other Agents And/or Comentioning

confidence: 84%

Section: Pharmacokineticsmentioning

confidence: 99%

Section: Transdermal Scopolamine Combined With Other Agents And/or Comentioning

confidence: 99%

Section: Timing Of Patch Applicationmentioning

confidence: 99%

See 2 more Smart Citations

Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting

Pergolizzi¹,

Philip²,

Leslie³

et al. 2012

Journal of Clinical Anesthesia

View full text Add to dashboard Cite

“…A few limitations of this study included the lack of a control-group without prophylaxis, PONV assessments were performed only for 24 h after surgery and all subjects had an indwelling urinary catheter; thus, the side effect of TDS on urinary retention was not assessed (15, 16). …”

Section: Discussionmentioning

confidence: 99%

Triple Therapy with Scopolamine, Ondansetron, and Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Moderate to High-Risk Patients Undergoing Craniotomy Under General Anesthesia: A Pilot Study

et al. 2015

View full text Add to dashboard Cite

IntroductionPostoperative nausea and vomiting (PONV) is one of the most common complaints from patients and clinicians after a surgical procedure. According to the current Society of Ambulatory Anesthesia Consensus Guidelines, the general incidence of vomiting and nausea is around 30 and 50%, respectively; and up to 80% in high-risk patients. In previous studies, the reported incidence of PONV at 24 h after craniotomy was 43–70%. The transdermal scopolamine (TDS) delivery system contains a 1.5-mg drug reservoir, which is designed to deliver a continuous slow release of scopolamine through intact skin during the first 72 h of patch application. Therefore, we designed this single arm, non-randomized, pilot study to assess the efficacy and safety of triple therapy with scopolamine, ondansetron, and dexamethasone to prevent PONV.Materials and methodsIn the preoperative area, subjects received an active TDS 1.5 mg that was applied to a hairless patch of skin in the mastoid area approximately 2 h prior to the operation. Immediately after anesthesia induction, all patients received a single 4 mg dose of ondansetron IV and a single 10 mg dose of dexamethasone IV. Patients who experienced nausea and/or vomiting received ondansetron 4 mg IV as the initial rescue medication. Postoperative nausea and vomiting assessments were performed for up to 120 h after surgery.ResultsA total of 36 subjects were analyzed. The overall incidence of PONV during the first 24 h after neurological surgery was 33% (n = 12). The incidence of nausea and emesis during the first 24 h after surgery was recorded as 33% (n = 12) and 16% (n = 6), respectively.ConclusionOur data showed that this triple therapy regimen may be an efficient alternative regimen for PONV prophylaxis in patients undergoing neurological surgery with general anesthesia. Further studies using regimens affecting different receptor pathways should be performed to better prove the efficacy and safety in the prevention or delay of PONV.

show abstract

Prophylactic transdermal scopolamine for the reduction of postoperative length of stay after uterine aspiration at Kaiser Permanente Northern California from 2017−2018

et al. 2022

View full text Add to dashboard Cite

Transdermal Scopolamine Patch with Odansetron for the Control of Nausea after Uterine Artery Embolization Compared with Odansetron Alone: Results of a Randomized Placebo–Controlled Trial

Cited by 6 publications

References 7 publications

Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting

Perspectives on transdermal scopolamine for the treatment of postoperative nausea and vomiting

Triple Therapy with Scopolamine, Ondansetron, and Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Moderate to High-Risk Patients Undergoing Craniotomy Under General Anesthesia: A Pilot Study

Prophylactic transdermal scopolamine for the reduction of postoperative length of stay after uterine aspiration at Kaiser Permanente Northern California from 2017−2018

Contact Info

Product

Resources

About